Natera, Inc. logo

Natera, Inc.

NTRA

NASDAQHealthcareMedical - Diagnostics & Research

Previous close

$332.03

+$7.19 · +2.21%

Aug 21, 4:00 PM ET

NTRA company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

65

Undervalued

Momentum

69

Gaining

Sentiment

47

Mixed

Risk resilience

57

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Natera, Inc. is a diagnostics company focused on developing and commercializing a wide array of molecular testing services globally. Its portfolio includes several key offerings: Panorama, a non-invasive prenatal test (NIPT) that screens for chromosomal abnormalities in a fetus using a blood sample from the mother, and also determines zygosity in twin pregnancies. Vistara, designed to identify single-gene disorders by screening for specific single-gene mutations. Horizon, a comprehensive carrier screening test to determine an individual's carrier status for various genetic diseases. Spectrum, utilized during in vitro fertilization (IVF) cycles to detect chromosomal anomalies or inherited genetic conditions. Anora, a miscarriage analysis product that examines fetal chromosomes to help understand the cause of pregnancy loss. Non-invasive paternity testing, which establishes paternity during gestation using blood samples from both the pregnant mother and the alleged father. Beyond reproductive health, Natera also provides specialized tests: Signatera, a sophisticated circulating tumor DNA (ctDNA) technology capable of screening for a generic set of mutations, independent of the individual's specific tumor characteristics. Prospera, a test used to assess and monitor organ transplant rejection. Additionally, the company offers Constellation, a cloud-based software platform that provides laboratory clients with access to Natera's proprietary algorithms and bioinformatics, enabling them to validate and launch their own tests. Natera distributes its products through a direct sales team and an extensive network of approximately 100 laboratory and distribution partners. The company has strategic partnerships, including one with BGI Genomics Co., Ltd. for the development, manufacturing, and commercialization of NGS-based genetic testing assays, and another with Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. Founded in 2003, Natera, Inc. is headquartered in Austin, Texas. It was formerly known as Gene Security Network, Inc. before changing its name in 2012.

Industry
Medical - Diagnostics & Research
Sector
Healthcare
Headquarters
US
CEO
Steven Leonard Chapman
Listed since
Jul 1, 2015
Employees
6,138

Market position

Day range

Current $332.03

52-week range

Current $332.03

Open
$321.61
Previous close
$324.84
Volume
1.22M
0.82× average
Average volume
1.48M
Average daily volume
Market cap
47.55B USD
Beta
1.51
Market reference 1
50-day average
$272.65
+21.78% above average
200-day average
$229.33
+44.78% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
30.46B USD
P/E (TTM)
-244.14×
P/B (TTM)
26.12×
P/S (TTM)
17.57×
EV / EBITDA
-138.12×
Earnings yield
-0.66%
Free cash flow yield
0.35%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
65.30%
Operating margin
-10.70%
Net margin
-7.11%
Return on equity
-12.16%
Return on assets
-8.30%
Return on invested capital
-11.13%

Financial health

Debt / equity
0.13×
Current ratio
3.39×
Altman Z-score
33.8
Piotroski F-score
3 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends79%23%-33%-89%Gross margin, FY2021: 49.09%Gross margin, FY2022: 44.37%Gross margin, FY2023: 45.52%Gross margin, FY2024: 60.30%Gross margin, FY2025: 64.85%Operating margin, FY2021: -74.85%Operating margin, FY2022: -65.96%Operating margin, FY2023: -41.22%Operating margin, FY2024: -13.10%Operating margin, FY2025: -13.44%Net margin, FY2021: -75.42%Net margin, FY2022: -66.79%Net margin, FY2023: -40.16%Net margin, FY2024: -11.22%Net margin, FY2025: -9.03%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 49.09%. Gross margin FY2022 44.37%. Gross margin FY2023 45.52%. Gross margin FY2024 60.30%. Gross margin FY2025 64.85%. Operating margin FY2021 -74.85%. Operating margin FY2022 -65.96%. Operating margin FY2023 -41.22%. Operating margin FY2024 -13.10%. Operating margin FY2025 -13.44%. Net margin FY2021 -75.42%. Net margin FY2022 -66.79%. Net margin FY2023 -40.16%. Net margin FY2024 -11.22%. Net margin FY2025 -9.03%.

Income trends

Revenue

2.31B USD+35.90%

Operating income

−309.91M USD-39.41%

Net income

−208.16M USD-9.31%
Income trends across reported periods2.59B USD1.45B USD308.37M USD−833.19M USDRevenue, FY2021: 625.49M USDRevenue, FY2022: 820.22M USDRevenue, FY2023: 1.08B USDRevenue, FY2024: 1.7B USDRevenue, FY2025: 2.31B USDOperating income, FY2021: −468.17M USDOperating income, FY2022: −541.04M USDOperating income, FY2023: −446.25M USDOperating income, FY2024: −222.29M USDOperating income, FY2025: −309.91M USDNet income, FY2021: −471.72M USDNet income, FY2022: −547.8M USDNet income, FY2023: −434.8M USDNet income, FY2024: −190.43M USDNet income, FY2025: −208.16M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 625.49M USD. Revenue FY2022 820.22M USD. Revenue FY2023 1.08B USD. Revenue FY2024 1.7B USD. Revenue FY2025 2.31B USD. Operating income FY2021 −468.17M USD. Operating income FY2022 −541.04M USD. Operating income FY2023 −446.25M USD. Operating income FY2024 −222.29M USD. Operating income FY2025 −309.91M USD. Net income FY2021 −471.72M USD. Net income FY2022 −547.8M USD. Net income FY2023 −434.8M USD. Net income FY2024 −190.43M USD. Net income FY2025 −208.16M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue2.31B USD1.7B USD1.08B USD820.22M USD625.49M USD
Cost of goods sold810.63M USD673.75M USD589.83M USD456.26M USD318.42M USD
Gross profit1.5B USD1.02B USD492.74M USD363.97M USD307.07M USD
Research and development624.11M USD404.14M USD320.68M USD316.42M USD264.21M USD
Selling, general, and administrative1.18B USD841.31M USD618.31M USD588.59M USD511.03M USD
Operating expenses1.81B USD1.25B USD938.99M USD905.01M USD775.24M USD
Interest income45.89M USD43.25M USD24.35M USD3.54M USD5.38M USD
Interest expense4.07M USD10.69M USD12.64M USD9.32M USD8.31M USD
Depreciation and amortization43.48M USD30.97M USD38.62M USD30.47M USD11.25M USD
Operating income−309.91M USD−222.29M USD−446.25M USD−541.04M USD−468.17M USD
Net income−208.16M USD−190.43M USD−434.8M USD−547.8M USD−471.72M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
64%
7 beats, 4 misses, 0 met estimates
Average EPS surprise
+22.04%
11 comparable reports
Latest EPS result
-0.47
Estimate -0.49 · Beat by 4.85%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.440.02-0.41-0.83Q1 '25MissQ2 '25BeatQ3 '25MissQ4 '25MissQ1 '26BeatQ2 '26MissQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 27, 2025: actual -0.41, estimate -0.381, surprise -7.57%, Miss. Q2 2025, reported May 8, 2025: actual -0.5, estimate -0.64, surprise +21.93%, Beat. Q3 2025, reported Aug 7, 2025: actual -0.74, estimate -0.615, surprise -20.24%, Miss. Q4 2025, reported Nov 6, 2025: actual -0.64, estimate -0.386, surprise -65.94%, Miss. Q1 2026, reported Feb 26, 2026: actual 0.35, estimate -0.512, surprise +168.35%, Beat. Q2 2026, reported May 7, 2026: actual -0.56, estimate -0.542, surprise -3.28%, Miss. Q3 2026, reported Aug 6, 2026: actual -0.47, estimate -0.494, surprise +4.85%, Beat. Q4 2026, reported Nov 5, 2026: actual —, estimate -0.224, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates782.86M657.08M531.31M405.53MQ1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 27, 2025: actual 476.06M USD, estimate 435.64M USD, surprise +9.28%, Beat. Q2 2025, reported May 8, 2025: actual 501.83M USD, estimate 446.23M USD, surprise +12.46%, Beat. Q3 2025, reported Aug 7, 2025: actual 546.6M USD, estimate 476.26M USD, surprise +14.77%, Beat. Q4 2025, reported Nov 6, 2025: actual 592.18M USD, estimate 513.45M USD, surprise +15.33%, Beat. Q1 2026, reported Feb 26, 2026: actual 665.5M USD, estimate 604.04M USD, surprise +10.18%, Beat. Q2 2026, reported May 7, 2026: actual 696.64M USD, estimate 617.1M USD, surprise +12.89%, Beat. Q3 2026, reported Aug 6, 2026: actual 752.75M USD, estimate 661.24M USD, surprise +13.84%, Beat. Q4 2026, reported Nov 5, 2026: actual —, estimate 706.87M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$319

3.92% downside
Past 12 months12-month forecastHigh $375Average $319Low $245

NTRA news

NTRA peers

ETFs holding NTRA

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research NTRA

research.disclaimer